• First Berlin reiterated its Buy on Pharming, cutting its 12-month target price to EUR 2.2 from EUR 2.4.
• Report cited weaker H1 2026 US Ruconest sales, down 11% year on year, pressured by inventory reductions.
• Analyst expects a rebound in H2, pointing to guidance implying a 3% full-year US revenue decline for Ruconest.
• First Berlin also highlighted pipeline catalysts, with Joenja phase 2 readouts due in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief via EQS News (Ref. ID: rc_26850) on September 18, 2026, and is solely responsible for the information contained therein.